ImmunoGen, Inc. Announces Favorable U...

ImmunoGen, Inc. Announces Favorable Update Provided by Roche Related to Its Trastuzumab-DM1 Regul...

There are 1 comment on the Customer Interaction Solutions story from Apr 17, 2010, titled ImmunoGen, Inc. Announces Favorable Update Provided by Roche Related to Its Trastuzumab-DM1 Regul.... In it, Customer Interaction Solutions reports that:

T-DM1 comprises ImmunoGen's DM1 cancer-cell killing agent linked to the HER2-targeting antibody, trastuzumab, developed by Genentech, a wholly owned member of the Roche Group.

Join the discussion below, or Read more at Customer Interaction Solutions.

cockmeatsammich

Canada

#1 Apr 18, 2010
test12

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

ImmunoGen Discussions

Title Updated Last By Comments
News Roche, ImmunoGen Bullseye Breast-Cancer Drug Wi... (Feb '13) Feb '13 gdpawel 1
More from around the web